We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Reinnervate to Launch Alvetex® in the United States at the SBS 17th Annual Conference
Product News

Reinnervate to Launch Alvetex® in the United States at the SBS 17th Annual Conference

Reinnervate to Launch Alvetex® in the United States at the SBS 17th Annual Conference
Product News

Reinnervate to Launch Alvetex® in the United States at the SBS 17th Annual Conference


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Reinnervate to Launch Alvetex® in the United States at the SBS 17th Annual Conference"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Reinnervate, has announce the upcoming US launch of alvetex® at the SBS 17th Annual Conference & Exhibition in Orlando, Florida (27-31 March 2011).

Alvetex® is a unique and proprietary cell culture scaffold that, for the first time, enables genuine 3D cell growth to be performed routinely and cost-effectively in cell biology laboratories. Using alvetex® enables researchers to grow cells in a manner that far more closely mimics their growth in vivo than is possible using traditional 2D techniques, greatly improving the accuracy and relevance of in vitro assays.

Reinnervate launched its first product, the alvetex® 12-well plate, in Europe at the end of November 2010 and it is currently available to researchers via LGC Standards, a leading supplier of cutting-edge research tools in Europe. The Company, which intends to launch alvetex® products in a range of formats over the next 12 months, will also use the conference to introduce the newest additions to its product range, the alvetex® 6-well and 12-well inserts.

The addition of the alvetex® well inserts will provide researchers with an exceptional degree of versatility in how they choose to construct different 3D cell culture models. Through enabling alternative applications, such as long-term 3D cell culture over several weeks, 3D cell growth at air/liquid interface and 3D cell growth with different media constituents, to be performed simply and routinely reinnervate continues to make genuine 3D cell culture a reality for researchers.

Tutorial and exhibition booth

In conjunction with the US launch of alvetex®, Professor Stefan Przyborski, founder and Chief Scientific Officer (CSO) of reinnervate, will be hosting a technical tutorial at SBS on the use of alvetex®, titled ‘Optimization of 3D Cell Growth using alvetex®’ at 8:00 am on Tuesday, 29th March (room: Miami 1/2). The tutorial will describe how alvetex® can be used to create 3D cell cultures of important cell lines routinely used in basic research, disease modeling, toxicity screening and drug safety testing.

To learn more about alvetex® and request a free evaluation of alvetex®, visit reinnervate at Booth 1131 at SBS 2011.

Ashley Cooper, CEO of reinnervate commenting on the US launch of alvetex®, said “The launch of alvetex® in the US and the global launch of our 6 and 12 well inserts is an important milestone for reinnervate as we work to meet the growing demand for our products among researchers around the world. In alvetex®, we believe we have a unique product that is capable of revolutionizing 3D cell culture and unlocking the enormous potential of this important area of scientific research. The game-changing nature of our product is being recognized and with the addition of the 6 and 12 well inserts can offer researchers the extra capability of creating very specific cell culture models that meet specific research needs.”

Advertisement